Roche (OTCMKTS:RHHBY) Rating Increased to Buy at Bank of America

Bank of America upgraded shares of Roche (OTCMKTS:RHHBY) from a neutral rating to a buy rating in a research note issued to investors on Friday morning, Marketbeat reports.

Other analysts have also recently issued reports about the stock. The Goldman Sachs Group began coverage on shares of Roche in a research note on Thursday, May 30th. They issued a sell rating on the stock. Deutsche Bank Aktiengesellschaft raised Roche from a sell rating to a hold rating in a research note on Friday, May 17th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of Hold.

Roche Stock Performance

OTCMKTS:RHHBY opened at $39.11 on Friday. Roche has a 1 year low of $29.20 and a 1 year high of $42.43. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.04 and a current ratio of 1.35. The stock’s fifty day moving average price is $39.59 and its two-hundred day moving average price is $34.85.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Cardinal Capital Management Inc. purchased a new position in Roche in the second quarter worth about $16,860,000. Saratoga Research & Investment Management lifted its stake in Roche by 6.9% during the 1st quarter. Saratoga Research & Investment Management now owns 2,458,918 shares of the company’s stock valued at $78,489,000 after acquiring an additional 158,482 shares during the period. Meritage Portfolio Management raised its holdings in shares of Roche by 186.9% during the first quarter. Meritage Portfolio Management now owns 174,714 shares of the company’s stock valued at $5,577,000 after purchasing an additional 113,823 shares during the last quarter. Hantz Financial Services Inc. purchased a new stake in Roche in the second quarter worth approximately $1,164,000. Finally, ORG Partners LLC purchased a new stake in Roche during the first quarter valued at $689,000.

About Roche

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.